首页> 美国卫生研究院文献>other >Clinical Outcome Assessments: Conceptual Foundation–Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force DOES THIS HAVE TO BE LABLED AS PART 1
【2h】

Clinical Outcome Assessments: Conceptual Foundation–Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force DOES THIS HAVE TO BE LABLED AS PART 1

机译:临床结果评估:概念基础– ISPOR临床结果评估的报告–结果研究工作组的新兴良好实践这是第1部分的内容

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An outcome assessment, the patient assessment used in an endpoint, is the measuring instrument that provides a rating or score (categorical or continuous) that is intended to represent some aspect of the patient’s health status. Outcome assessments are used to define efficacy endpoints when developing a therapy for a disease or condition. Most efficacy endpoints are based on specified clinical assessments of patients. When clinical assessments are used as clinical trial outcomes, they are called clinical outcome assessments (COAs).COAs include any assessment that may be influenced by human choices, judgment, or motivation, COAs must be well-defined and possess adequate measurement properties in order to demonstrate (directly or indirectly) the benefits of a treatment. In contrast, a biomarker assessment is one that is subject to little, if any, patient motivational or rater judgmental influence.This is the first of two reports by the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force. This report provides foundational definitions important for an understanding of COA measurement principles. The foundation provided in this report includes what it means to demonstrate a beneficial effect, how assessments of patients relate to the objective of showing a treatment’s benefit, and how these assessments are used in clinical trial endpoints.In addition, this report describes intrinsic attributes of patient assessments and clinical trial factors that can affect the properties of the measurements. These factors should be considered when developing or refining assessments. These considerations will aid investigators designing trials in their choice of using an existing assessment or developing a new outcome assessment. Although the focus of this report is in the development of a new COA to define endpoints in a clinical trial, these principles may be applied more generally.A critical element in appraising or developing a COA is to describe the treatment’s intended benefit as an effect on a clearly identified aspect of how a patient feels or functions. This aspect must have importance to the patient and be part of their typical life. This meaningful health aspect can be measured directly or measured indirectly when it is impractical to evaluate it directly or difficult to measure. For indirect measurement, a concept of interest (COI) can be identified. The COI must be related to how a patient feels or functions. Procedures are then developed to measure the concept of interest. The relationship of these measurements to how a patient feels or functions in the intended setting and manner of use of the COA (the context of use) could then be defined.A COA has identifiable attributes or characteristics that affect the measurement properties of the COA when used in endpoints. One of these features is whether judgment can influence the measurement, and if so, whose judgment. This attribute defines four categories of COAs: Patient-reported outcomes (PROs), clinician-reported outcomes (ClinROs), observer-reported outcomes (ObsROs), and performance outcomes (PerfOs). A full description is included in this report as well as explanation of other important COA features. The information in this report should aid in the development, refinement and standardization of COAs, and ultimately, improve their measurement properties.
机译:结果评估(端点中使用的患者评估)是一种测量工具,可提供旨在代表患者健康状况某些方面的等级或评分(分类或连续)。结果评估用于定义针对疾病或状况的疗法时的疗效终点。大多数功效终点均基于对患者的特定临床评估。当将临床评估结果用作临床试验结果时,它们称为临床结果评估结果(COA).COA包括任何可能受到人为选择,判断或动机影响的评估,因此COA必须定义明确并具有适当的测量属性证明(直接或间接)治疗的益处。相比之下,生物标志物评估受患者动机或评估者的判断影响很小(如果有的话)。这是ISPOR临床结果评估–新兴的良好结果实践研究工作组的两项报告中的第一篇。该报告提供了基本的定义,对于理解COA度量原则非常重要。本报告提供的基础包括证明有益效果的含义,对患者的评估如何与显示治疗益处的目标相关联,以及如何将这些评估用于临床试验终点。此外,本报告还描述了药物的内在属性。可能影响测量属性的患者评估和临床试验因素。在制定或完善评估时应考虑这些因素。这些考虑因素将有助于研究人员选择使用现有评估或开发新结果评估来设计试验。尽管本报告的重点是开发新的COA来定义临床试验中的终点,但这些原则可能会更广泛地应用。评估或开发COA的关键要素是描述治疗的预期获益是对治疗的影响病人感觉或功能的清晰识别方面。这方面必须对患者具有重要性,并应成为他们典型生活的一部分。当无法直接评估或难以评估时,可以直接或间接地评估此有意义的健康状况。对于间接测量,可以确定感兴趣的概念(COI)。 COI必须与患者的感觉或功能有关。然后制定程序来衡量兴趣概念。然后可以定义这些测量值与患者在COA的预期设置和使用方式(使用背景)中的感觉或功能的关系.COA具有可识别的属性或特性,这些属性或特性会在以下情况下影响COA的测量特性在端点中使用。这些特征之一是判断是否会影响测量,如果是,则会影响谁的判断。此属性定义了COA的四类:患者报告的结果(PRO),临床医生报告的结果(ClinROs),观察者报告的结果(ObsROs)和绩效结果(PerfOs)。此报告中包含完整说明,以及其他重要COA功能的说明。本报告中的信息应有助于COA的开发,完善和标准化,并最终改善其测量性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号